Bioiberica to present their latest scientific findings on osteoarthritis at the 43th meeting of the Spanish Society of Rheumatology

Bioibérica is present at the 43th meeting of the Spanish Society of Rheumatology, sponsoring the discussion panel “Latest lines of research in osteoarthritis” (Wednesday 24 May, 10-11 AM, room 4), in which they presented new trials and scientific advances in the treatment of this condition, which affects seven million Spaniards.

One of the highlighted lectures is the one presented by Dr. Pedro Zapater, from the Clinical Pharmacology Unit of the University Hospital of Alicante, entitled ”Role of the adrenergic system in OA progression”, done in collaboration with Bioiberica. In osteoarthritis, the adrenergic system has been associated with loss of subchondral bone and an increase in osteoclast activity.

By analyzing the serum of participants in the MOVES clinical essay, they have identified patients with an specific activation profile of the immune-inflammatory and adrenergic system which could imply a different development of the disease, both at the symptomatic and joint damage levels. Furthermore, they have observed that a treatment based on a combination of chondroitin sulfate and glucosamine modulates the adrenergic activation of these patients, proving the protective effect of this drug for joint structures. The MOVES clinical essay has proved that the combination of glucosamine with chondroitin sulfate or Droglican®, Bioibérica, has an effect comparable to that of the benchmark product celecoxib.

In addition, the paper entitled “Combinación de condroitín sulfato y glucosamina para el tratamiento de enfermedades musculo esqueléticas y artrosis: ¿la oportunidad para matar dos pájaros de un tiro? (Using a combination of chondroitin sulfate and glucosamine for the treatment of musculoskeletal diseases and osteoarthritis: a chance to kill two birds with one stone?), carried out by Bioiberica in collaboration with the  Fundación FC Barcelona and the Centro Tecnológico Leitat, has been selected to the presented as the Poster Tour of Friday 26 May, in the early morning.

The results of this study proved the therapeutic effect of chondroitin sulfate and glucosamine in an experimental, validated animal model which mimics very well the typical injuries suffered by professional sportspersons. More precisely, they suggest that the combination of these compounds is able to accelerate the muscle regeneration process which takes place after an injury (reducing fibrosis and increasing muscle strength), thus becoming potential candidates for the development of new therapy in the field of sports medicine.

Bioiberica will be present at the exhibitors’ area, more precisely at booth #12.